牛牛AI助理已提取核心訊息
On January 26, 2024, Cardio Diagnostics Holdings, Inc. entered into a Sales Agreement with Craig-Hallum Capital Group LLC, allowing the company to sell up to $17 million in shares of its common stock at its discretion. The sales will be conducted as an 'at the market' offering under the company's effective Registration Statement, which was declared effective by the SEC on February 1, 2024. The company has the flexibility to determine the parameters of the share sales, including the number, timing, and minimum price of shares to be sold. Cardio Diagnostics Holdings will pay Craig-Hallum a 2.5% commission on the gross proceeds from the sales and will cover certain legal costs associated with the agreement. The offering will end when the total sales reach $17 million or upon termination of the Sales Agreement by either party. The net proceeds are intended for general corporate purposes. The company has made customary representations and warranties and has agreed to indemnify Craig-Hallum against certain liabilities.
On January 26, 2024, Cardio Diagnostics Holdings, Inc. entered into a Sales Agreement with Craig-Hallum Capital Group LLC, allowing the company to sell up to $17 million in shares of its common stock at its discretion. The sales will be conducted as an 'at the market' offering under the company's effective Registration Statement, which was declared effective by the SEC on February 1, 2024. The company has the flexibility to determine the parameters of the share sales, including the number, timing, and minimum price of shares to be sold. Cardio Diagnostics Holdings will pay Craig-Hallum a 2.5% commission on the gross proceeds from the sales and will cover certain legal costs associated with the agreement. The offering will end when the total sales reach $17 million or upon termination of the Sales Agreement by either party. The net proceeds are intended for general corporate purposes. The company has made customary representations and warranties and has agreed to indemnify Craig-Hallum against certain liabilities.
2024年1月26日，Cardio Diagnostics Holdings, Inc.與Craig-Hallum Capital Group LLC簽訂了銷售協議，允許該公司自行決定出售高達1700萬美元的普通股。根據該公司的有效註冊聲明，此次銷售將作爲 “在市場上發行” 進行，該聲明已由美國證券交易委員會於2024年2月1日宣佈生效。公司可以靈活地確定股票銷售的參數，包括出售股票的數量、時間和最低價格。Cardio Diagnostics Holdings將根據銷售總收益向Craig-Hallum支付2.5％的佣金，並將支付與該協議相關的某些法律費用。當總銷售額達到1700萬美元或任何一方終止銷售協議時，此次發行將結束。淨收益用於一般公司用途。該公司已作出慣常陳述和保證，並同意向Craig-Hallum賠償某些責任。
2024年1月26日，Cardio Diagnostics Holdings, Inc.與Craig-Hallum Capital Group LLC簽訂了銷售協議，允許該公司自行決定出售高達1700萬美元的普通股。根據該公司的有效註冊聲明，此次銷售將作爲 “在市場上發行” 進行，該聲明已由美國證券交易委員會於2024年2月1日宣佈生效。公司可以靈活地確定股票銷售的參數，包括出售股票的數量、時間和最低價格。Cardio Diagnostics Holdings將根據銷售總收益向Craig-Hallum支付2.5％的佣金，並將支付與該協議相關的某些法律費用。當總銷售額達到1700萬美元或任何一方終止銷售協議時，此次發行將結束。淨收益用於一般公司用途。該公司已作出慣常陳述和保證，並同意向Craig-Hallum賠償某些責任。
有用
沒用